

Resource Summary Report

Generated by [Kravitz](#) on Sep 10, 2026

NanoString: GeoMx Digital Spatial Profiler

RRID:SCR_021660

Type: Tool

Proper Citation

NanoString: GeoMx Digital Spatial Profiler (RRID:SCR_021660)

Resource Information

URL: <https://www.nanostring.com/products/geomx-digital-spatial-profiler/geomx-dsp-overview/>

Proper Citation: NanoString: GeoMx Digital Spatial Profiler (RRID:SCR_021660)

Description: Integrated commercial system comprising hardware, software and nCounter chemistry that enables simultaneous, highly multiplex spatial profiling of proteins or RNA in FFPE tissues. DSP platform quantifies abundance of protein or RNA by counting unique indexing oligonucleotides assigned to each target of interest. Used to rapidly and quantitatively assess biological implications of heterogeneity within tissue samples.

Abbreviations: GeoMx DSP

Synonyms: GeoMx Digital Spatial Profiler

Resource Type: instrument resource

Defining Citation: [PMID:32393914](#)

Keywords: Spatial profiling, proteins spatial profiling, RNA spatial profiling, NanoString, counting unique indexing oligonucleotides, tissue heterogeneity, Digital Spatial Profiler, instrument, equipment, USEdit

Availability: Restricted

Resource Name: NanoString: GeoMx Digital Spatial Profiler

Resource ID: SCR_021660

Record Creation Time: 20220129T080356+0000

Record Last Update: 20260905T132944+0000

Ratings and Alerts

No rating or validation information has been found for NanoString: GeoMx Digital Spatial Profiler.

No alerts have been found for NanoString: GeoMx Digital Spatial Profiler.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 34 mentions in open access literature.

Listed below are recent publications. The full list is available at [Kravitz](#) .

Savani MR, et al. (2026) Stable isotope tracing in human plasma-like medium reveals metabolic and immune modulation of the glioblastoma microenvironment. *Neuro-oncology*, 28(2), 415.

Spalato Ceruso M, et al. (2026) Adenosine A2B Receptor Promotes Tumor Progression and Metastases in Undifferentiated Pleomorphic Sarcoma. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 32(9), 1887.

Hu YM, et al. (2026) Elevated Tumor-Associated Androgen Receptor Activity Correlates with Poor Immune Infiltration and Immunotherapy Response across Cancer Types. *Cancer research communications*, 6(1), 17.

Cen X, et al. (2026) Single-Cell and Spatial Omics: Methods and Applications. *MedComm*, 7(4), e70713.

Baurès M, et al. (2026) Targeting pre-existing club-like cells in prostate cancer potentiates androgen deprivation therapy. *EMBO molecular medicine*, 18(3), 943.

Kimura N, et al. (2026) CLDN6 Expression Plasticity in Ovarian Cancer: Insights into Therapeutic Optimization for CLDN6-Targeted Immunotherapy. *Cancer research communications*, 6(2), 383.

Peña AN, et al. (2026) Acellular Adipose Tissue promotes anti-fibrotic remodeling in Phase II Study. *medRxiv : the preprint server for health sciences*.

Garcia J, et al. (2026) Immune checkpoint inhibitors amplify type 2 immune mediated repair by pro-regenerative scaffolds. *bioRxiv : the preprint server for biology*.

Marceaux C, et al. (2026) TNF- α -mediated myeloid-instructed CD14⁺CD4⁺ T cells are associated with poor survival in lung adenocarcinoma. *Cell reports. Medicine*, 7(2), 102593.

Djureinovic D, et al. (2026) CD40 agonism in renal cell carcinoma enhances immune checkpoint activity through myeloid cells. *iScience*, 29(7), 116527.

Lin EW, et al. (2026) Therapeutic Targeting of Epithelial-Mesenchymal Cellular Plasticity in Pancreatic Cancer. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 32(5), 869.

van Oost S, et al. (2026) Immune infiltration is associated with distinct transcriptional states and metabolic profiles in chordomas. *iScience*, 29(5), 115668.

Knisely A, et al. (2025) Surgical and Blood-Based Minimal Residual Disease in Patients with Ovarian Cancer after First-line Therapy: Clinical Outcomes and Translational Opportunities. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 31(19), 4122.

Burns GW, et al. (2025) Spatial transcriptomic analysis identifies epithelium-macrophage crosstalk in endometriotic lesions. *iScience*, 28(2), 111790.

Gregory RC, et al. (2025) In Situ Proinflammatory Effects of Dazostinag Alone or with Chemotherapy on the Tumor Microenvironment of Patients with Head and Neck Squamous Cell Carcinoma. *Cancer research communications*, 5(7), 1243.

Li J, et al. (2025) Mutational Analysis of Early, Low-Grade Bowel Polyps Defines a Subgroup with Concurrent, High-Risk Oncogenic Drivers Independent of Polyp Size. *Cancer research communications*, 5(8), 1372.

Garcia GL, et al. (2025) Aged and BRCA-Mutated Stromal Cells Drive Epithelial Cell Transformation. *Cancer discovery*, 15(6), 1203.

Rademacher K, et al. (2025) Chronic hyperactivation of midbrain dopamine neurons causes preferential dopamine neuron degeneration. *eLife*, 13.

Kim S, et al. (2025) Remodeling of tumor microenvironments by EGFR tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer. *iScience*, 28(2), 111736.

Lim SH, et al. (2025) Determinants of Response to Sequential Pembrolizumab with Trastuzumab plus Platinum/5-FU in HER2-Positive Gastric Cancer: A Phase II Chemoimmunotherapy Trial. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 31(8), 1476.